Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rein Therapeutics (RNTX) EPS (Weighted Average and Diluted) (2021 - 2025)

Rein Therapeutics (RNTX) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with -$0.21 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 16.67% to -$0.21 in Q3 2025 year-over-year; TTM through Sep 2025 was -$2.94, a 3.92% increase, with the full-year FY2024 number at -$3.51, down 2.63% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.21 for Q3 2025 at Rein Therapeutics, up from -$0.28 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.07 in Q2 2021 to a low of -$5.67 in Q4 2021.
  • A 5-year average of -$1.02 and a median of -$0.43 in 2024 define the central range for EPS (Weighted Average and Diluted).
  • Biggest YoY gain for EPS (Weighted Average and Diluted) was 82.36% in 2022; the steepest drop was 2557.88% in 2022.
  • Rein Therapeutics' EPS (Weighted Average and Diluted) stood at -$5.67 in 2021, then soared by 82.36% to -$1.0 in 2022, then plummeted by 57.0% to -$1.57 in 2023, then plummeted by 40.13% to -$2.2 in 2024, then soared by 90.45% to -$0.21 in 2025.
  • Per Business Quant, the three most recent readings for RNTX's EPS (Weighted Average and Diluted) are -$0.21 (Q3 2025), -$0.28 (Q2 2025), and -$0.25 (Q1 2025).